Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent radiotherapy with nab-paclitaxel plus cisplatin for advanced esophageal squamous cell carcinoma
ChiCTR1900021079Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Clinical complete response rate. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900021079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021079.